Formulations and doses of pegylated uricase
AssigneeCartesian Therapeutics, Inc.
InventorsLloyd Johnston, Takashi Kei Kishimoto, Earl Sands, Werner Cautreels
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions and kits related to identification and/or treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.
Claims37
A method, comprising:
- obtaining an anti-uricase antibody level (e.g., a titer) in any one of the subjects provided herein, such as in a sample from the subject, and
- assessing the subject for treatment of any one of the conditions provided herein.
(canceled)
A method, comprising:
- concomitantly administering to a subject having an anti-uricase antibody level (e.g., a titer) below a threshold, 1) a composition comprising synthetic nanocarriers comprising an immunosuppressant and 2) a composition comprising uricase.
(canceled)
(canceled)
A method, comprising,
- identifying a subject as having an anti-uricase antibody level (e.g., titer) below a threshold and treating the subject.
10-13. (canceled)
A method of preventing gout flare, comprising:
- concomitantly administering to a subject having an anti-uricase antibody level (e.g., titer) below a threshold, 1) a composition comprising synthetic nanocarriers comprising an immunosuppressant and 2) a composition comprising uricase, wherein the subject is not administered an additional therapeutic to prevent gout flare concomitantly with the concomitant administration.
15-17. (canceled)
19-21. (canceled)
24-27. (canceled)
29-31. (canceled)
(canceled)
(canceled)
(canceled)
39-48. (canceled)
50-82. (canceled)
A method, comprising:
- administering to any one of the subjects described herein having an anti-uricase antibody level (e.g., titer) below a threshold, a composition comprising uricase at any one of the doses provided herein and a pharmaceutically acceptable carrier one or more times.
84-96. (canceled)
A method, comprising
- concomitantly administering to a subject having an anti-uricase antibody level (e.g., titer) below a threshold, 1) a composition comprising polymeric synthetic nanocarriers comprising PLA, PLA-PEG, and rapamycin;
- and 2) a composition comprising uricase, wherein the composition comprising polymeric synthetic nanocarriers comprising PLA, PLA-PEG, and rapamycin is administered at a dose of 0.05 mg/kg-0.3 mg/kg rapamcyin and the dose of the composition comprising uricase is 0.1 mg/kg-0.5 mg/kg.
98-112. (canceled)
A method, comprising:
- concomitantly administering to a subject having an anti-uricase antibody level (e.g., titer) below a threshold, 1) a composition comprising polymeric synthetic nanocarriers comprising rapamycin;
- and 2) a composition comprising pegsiticase, wherein the composition comprising polymeric synthetic nanocarriers is administered at a dose of 0.05 mg/kg-0.3 mg/kg rapamycin and the dose of the composition comprising pegsiticase is 0.1 mg/kg-0.5 mg/kg pegsiticase.
114-132. (canceled)
(canceled)
Dependencies are inferred from the claim text.